Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Abstract

Progression-free survival was significantly longer with first-line nivolumab plus ipilimumab than with chemotherapy among patients with NSCLC and a high tumor mutational burden, irrespective of PD-L1 expression level. The results validate the benefit of nivolumab plus ipilimumab in NSCLC and the role of tumor mutational burden as a biomarker for patient selection. (Funded by Bristol-Myers Squibb and Ono Pharmaceut

Keywords

Affiliated Institutions

• The Netherlands Cancer Institute NL
• Fundación Arturo López Pérez CL
• Seoul National University Bundang Hospital KR
• Bristol-Myers Squibb (United States) US
• Hôpital d'Instruction des Armées Sainte-Anne FR
• Iuliu Hațieganu University of Medicine and Pharmacy RO
• The Ohio State University US
• Fox Chase Cancer Center US
• Emory University US
• Sidney Kimmel Comprehensive Cancer Center US
• Cancer Institute (WIA) IN
• Metropolitan Hospital GR
• Institute of Oncology Prof. Dr. Ion Chiricuta RO
• Hospital Universitario 12 De Octubre ES
• Memorial Sloan Kettering Cancer Center US
• Centrum Onkologii PL
• Ospedale Santa Maria IT
• LungenClinic Grosshansdorf DE
• Princess Alexandra Hospital AU
• German Center for Lung Research DE

Related Publications